25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GeneBioTech Co. Ltd
Buy, Hold or Sell?

Let's analyze Genebiotech together

I guess you are interested in GeneBioTech Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GeneBioTech Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about GeneBioTech Co. Ltd

I send you an email if I find something interesting about GeneBioTech Co. Ltd.

1. Quick Overview

1.1. Quick analysis of Genebiotech (30 sec.)










1.2. What can you expect buying and holding a share of Genebiotech? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
67.5%

What is your share worth?

Current worth
₩5,738.97
Expected worth in 1 year
₩6,014.64
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
₩275.66
Return On Investment
8.0%

For what price can you sell your share?

Current Price per Share
₩3,460.00
Expected price per share
₩3,125 - ₩3,700
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Genebiotech (5 min.)




Live pricePrice per Share (EOD)
₩3,460.00

2.2. Growth of Genebiotech (5 min.)




Is Genebiotech growing?

Current yearPrevious yearGrowGrow %
How rich?$34.5m$32m$2m5.9%

How much money is Genebiotech making?

Current yearPrevious yearGrowGrow %
Making money$424.5k$454.9k-$30.3k-7.2%
Net Profit Margin3.0%3.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Genebiotech (5 min.)




2.4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Genebiotech?

Welcome investor! Genebiotech's management wants to use your money to grow the business. In return you get a share of Genebiotech.

First you should know what it really means to hold a share of Genebiotech. And how you can make/lose money.

Speculation

The Price per Share of Genebiotech is ₩3,460. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genebiotech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genebiotech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩5,738.97. Based on the TTM, the Book Value Change Per Share is ₩68.92 per quarter. Based on the YOY, the Book Value Change Per Share is ₩77.95 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genebiotech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.040.0%0.050.0%0.050.0%0.020.0%0.030.0%
Usd Book Value Change Per Share0.020.0%0.050.0%0.050.0%0.020.0%0.050.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.020.0%0.050.0%0.050.0%0.030.0%0.070.0%
Usd Price Per Share2.77-2.90-2.91-3.52-3.54-
Price to Earnings Ratio15.74-15.72--2.40-5.53-21.01-
Price-to-Total Gains Ratio112.09-69.79-12.16-84.52-42.51-
Price to Book Ratio0.69-0.73-0.78-0.94-1.12-
Price-to-Total Gains Ratio112.09-69.79-12.16-84.52-42.51-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.422
Number of shares412
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.050.02
Usd Total Gains Per Share0.050.03
Gains per Quarter (412 shares)19.8812.64
Gains per Year (412 shares)79.5050.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
108070173341
20159150356792
3023923052100143
4031831069133194
5039839087166245
60477470104200296
70557550121233347
80636630138266398
90716710156299449
100795790173333500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%9.03.00.075.0%14.06.00.070.0%33.07.00.082.5%36.07.03.078.3%
Book Value Change Per Share4.00.00.0100.0%9.03.00.075.0%13.07.00.065.0%28.012.00.070.0%32.014.00.069.6%
Dividend per Share0.00.04.00.0%2.00.010.016.7%10.00.010.050.0%27.00.013.067.5%29.00.017.063.0%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%16.04.00.080.0%31.09.00.077.5%35.011.00.076.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of GeneBioTech Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--35.28368.915-49%77.948-55%28.826+22%75.114-53%
Book Value Per Share--5738.9755651.544+2%5316.765+8%5351.132+7%4710.853+22%
Current Ratio--2.9253.153-7%3.002-3%3.443-15%2.394+22%
Debt To Asset Ratio--0.2990.287+4%0.290+3%0.293+2%0.356-16%
Debt To Equity Ratio--0.4260.404+6%0.410+4%0.417+2%0.555-23%
Dividend Per Share----0%-0%15.000-100%19.627-100%
Eps--62.81170.437-11%75.480-17%31.722+98%46.739+34%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap28961791600.000-18%34054871585.00035658593413.750-4%35755474975.000-5%43345727642.750-21%43187211378.875-21%
Net Profit Margin--0.0270.030-12%0.031-14%0.013+104%0.025+8%
Operating Margin----0%0.0000%0.001-100%0.014-100%
Operating Ratio--1.6791.759-5%1.530+10%1.274+32%1.250+34%
Pb Ratio0.603-14%0.6890.733-6%0.781-12%0.945-27%1.116-38%
Pe Ratio13.771-14%15.74215.720+0%-2.402+115%5.530+185%21.008-25%
Price Per Share3460.000-14%3955.0004141.250-4%4152.500-5%5034.000-21%5059.625-22%
Price To Free Cash Flow Ratio---20.237-100%13.110-100%4.568-100%14.370-100%
Price To Total Gains Ratio98.063-14%112.09369.792+61%12.156+822%84.515+33%42.507+164%
Quick Ratio---0.988-100%2.129-100%2.659-100%1.932-100%
Return On Assets--0.0080.009-13%0.010-24%0.003+176%0.006+31%
Return On Equity--0.0110.012-12%0.014-22%0.004+170%0.009+18%
Total Gains Per Share--35.28368.915-49%77.948-55%43.826-19%94.741-63%
Usd Book Value--34591158.70034064175.908+2%32046335.659+8%32253492.401+7%28208047.120+23%
Usd Book Value Change Per Share--0.0250.048-49%0.055-55%0.020+22%0.053-53%
Usd Book Value Per Share--4.0173.956+2%3.722+8%3.746+7%3.298+22%
Usd Dividend Per Share----0%-0%0.010-100%0.014-100%
Usd Eps--0.0440.049-11%0.053-17%0.022+98%0.033+34%
Usd Free Cash Flow---665141.176-100%351458.109-100%-559657.8690%134141.562-100%
Usd Market Cap20273254.120-18%23838410.11024961015.390-4%25028832.483-5%30342009.350-21%30231047.965-21%
Usd Price Per Share2.422-14%2.7692.899-4%2.907-5%3.524-21%3.542-22%
Usd Profit--378589.400424554.212-11%454947.357-17%138036.305+174%251887.497+50%
Usd Revenue--14240912.00014004965.809+2%14856988.864-4%14716284.156-3%12307044.976+16%
Usd Total Gains Per Share--0.0250.048-49%0.055-55%0.031-19%0.066-63%
 EOD+3 -4MRQTTM+9 -19YOY+7 -215Y+15 -1510Y+18 -13

3.3 Fundamental Score

Let's check the fundamental score of GeneBioTech Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513.771
Price to Book Ratio (EOD)Between0-10.603
Net Profit Margin (MRQ)Greater than00.027
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than12.925
Debt to Asset Ratio (MRQ)Less than10.299
Debt to Equity Ratio (MRQ)Less than10.426
Return on Equity (MRQ)Greater than0.150.011
Return on Assets (MRQ)Greater than0.050.008
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of GeneBioTech Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.320
Ma 20Greater thanMa 503,452.750
Ma 50Greater thanMa 1003,469.700
Ma 100Greater thanMa 2003,651.200
OpenGreater thanClose3,435.000
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About GeneBioTech Co. Ltd

Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.

Fundamental data was last updated by Penke on 2024-11-18 20:32:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Genebiotech earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Genebiotech to the Pharmaceuticals industry mean.
  • A Net Profit Margin of 2.7% means that ₩0.03 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GeneBioTech Co. Ltd:

  • The MRQ is 2.7%. The company is making a profit. +1
  • The TTM is 3.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.7%TTM3.0%-0.4%
TTM3.0%YOY3.1%-0.1%
TTM3.0%5Y1.3%+1.7%
5Y1.3%10Y2.5%-1.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7%9.8%-7.1%
TTM3.0%9.5%-6.5%
YOY3.1%9.9%-6.8%
5Y1.3%12.9%-11.6%
10Y2.5%12.6%-10.1%
4.3.1.2. Return on Assets

Shows how efficient Genebiotech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genebiotech to the Pharmaceuticals industry mean.
  • 0.8% Return on Assets means that Genebiotech generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GeneBioTech Co. Ltd:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.9%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.8%TTM0.9%-0.1%
TTM0.9%YOY1.0%-0.1%
TTM0.9%5Y0.3%+0.6%
5Y0.3%10Y0.6%-0.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8%3.6%-2.8%
TTM0.9%3.5%-2.6%
YOY1.0%5.3%-4.3%
5Y0.3%5.9%-5.6%
10Y0.6%4.9%-4.3%
4.3.1.3. Return on Equity

Shows how efficient Genebiotech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genebiotech to the Pharmaceuticals industry mean.
  • 1.1% Return on Equity means Genebiotech generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GeneBioTech Co. Ltd:

  • The MRQ is 1.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.1%TTM1.2%-0.2%
TTM1.2%YOY1.4%-0.2%
TTM1.2%5Y0.4%+0.8%
5Y0.4%10Y0.9%-0.5%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1%4.6%-3.5%
TTM1.2%4.6%-3.4%
YOY1.4%8.2%-6.8%
5Y0.4%9.1%-8.7%
10Y0.9%10.3%-9.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of GeneBioTech Co. Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Genebiotech is operating .

  • Measures how much profit Genebiotech makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genebiotech to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GeneBioTech Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY0.0%+0.0%
TTM-5Y0.1%-0.1%
5Y0.1%10Y1.4%-1.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-13.2%
TTM-12.0%-12.0%
YOY0.0%12.4%-12.4%
5Y0.1%8.6%-8.5%
10Y1.4%12.1%-10.7%
4.3.2.2. Operating Ratio

Measures how efficient Genebiotech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.68 means that the operating costs are ₩1.68 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of GeneBioTech Co. Ltd:

  • The MRQ is 1.679. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.759. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.679TTM1.759-0.080
TTM1.759YOY1.530+0.229
TTM1.7595Y1.274+0.485
5Y1.27410Y1.250+0.024
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6791.225+0.454
TTM1.7591.220+0.539
YOY1.5301.311+0.219
5Y1.2741.249+0.025
10Y1.2501.240+0.010
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of GeneBioTech Co. Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Genebiotech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 2.93 means the company has ₩2.93 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of GeneBioTech Co. Ltd:

  • The MRQ is 2.925. The company is able to pay all its short-term debts. +1
  • The TTM is 3.153. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.925TTM3.153-0.227
TTM3.153YOY3.002+0.151
TTM3.1535Y3.443-0.290
5Y3.44310Y2.394+1.049
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9252.213+0.712
TTM3.1532.234+0.919
YOY3.0022.028+0.974
5Y3.4432.199+1.244
10Y2.3941.995+0.399
4.4.3.2. Quick Ratio

Measures if Genebiotech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genebiotech to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GeneBioTech Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.988-0.988
TTM0.988YOY2.129-1.142
TTM0.9885Y2.659-1.671
5Y2.65910Y1.932+0.727
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.926-0.926
TTM0.9880.973+0.015
YOY2.1291.515+0.614
5Y2.6591.591+1.068
10Y1.9321.399+0.533
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of GeneBioTech Co. Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Genebiotech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genebiotech to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.30 means that Genebiotech assets are financed with 29.9% credit (debt) and the remaining percentage (100% - 29.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GeneBioTech Co. Ltd:

  • The MRQ is 0.299. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.287. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.299TTM0.287+0.011
TTM0.287YOY0.290-0.003
TTM0.2875Y0.293-0.005
5Y0.29310Y0.356-0.063
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2990.345-0.046
TTM0.2870.339-0.052
YOY0.2900.333-0.043
5Y0.2930.315-0.022
10Y0.3560.339+0.017
4.5.4.2. Debt to Equity Ratio

Measures if Genebiotech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genebiotech to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 42.6% means that company has ₩0.43 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GeneBioTech Co. Ltd:

  • The MRQ is 0.426. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.404. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.426TTM0.404+0.022
TTM0.404YOY0.410-0.006
TTM0.4045Y0.417-0.014
5Y0.41710Y0.555-0.137
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4260.547-0.121
TTM0.4040.547-0.143
YOY0.4100.499-0.089
5Y0.4170.476-0.059
10Y0.5550.548+0.007
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Genebiotech generates.

  • Above 15 is considered overpriced but always compare Genebiotech to the Pharmaceuticals industry mean.
  • A PE ratio of 15.74 means the investor is paying ₩15.74 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GeneBioTech Co. Ltd:

  • The EOD is 13.771. Based on the earnings, the company is underpriced. +1
  • The MRQ is 15.742. Based on the earnings, the company is fair priced.
  • The TTM is 15.720. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD13.771MRQ15.742-1.970
MRQ15.742TTM15.720+0.022
TTM15.720YOY-2.402+18.122
TTM15.7205Y5.530+10.189
5Y5.53010Y21.008-15.478
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD13.77127.863-14.092
MRQ15.74229.844-14.102
TTM15.72027.532-11.812
YOY-2.40223.102-25.504
5Y5.53027.577-22.047
10Y21.00829.248-8.240
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GeneBioTech Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM20.237-20.237
TTM20.237YOY13.110+7.127
TTM20.2375Y4.568+15.669
5Y4.56810Y14.370-9.803
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.531-29.531
TTM20.23729.447-9.210
YOY13.11026.360-13.250
5Y4.56831.734-27.166
10Y14.37034.357-19.987
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Genebiotech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 0.69 means the investor is paying ₩0.69 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of GeneBioTech Co. Ltd:

  • The EOD is 0.603. Based on the equity, the company is cheap. +2
  • The MRQ is 0.689. Based on the equity, the company is cheap. +2
  • The TTM is 0.733. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.603MRQ0.689-0.086
MRQ0.689TTM0.733-0.044
TTM0.733YOY0.781-0.048
TTM0.7335Y0.945-0.212
5Y0.94510Y1.116-0.171
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD0.6034.659-4.056
MRQ0.6893.381-2.692
TTM0.7333.209-2.476
YOY0.7812.597-1.816
5Y0.9453.278-2.333
10Y1.1164.179-3.063
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets70,469,490
Total Liabilities21,053,549
Total Stockholder Equity49,415,942
 As reported
Total Liabilities 21,053,549
Total Stockholder Equity+ 49,415,942
Total Assets = 70,469,490

Assets

Total Assets70,469,490
Total Current Assets54,623,521
Long-term Assets15,845,970
Total Current Assets
Total Current Assets  (as reported)54,623,521
Total Current Assets  (calculated)0
+/- 54,623,521
Long-term Assets
Long-term Assets  (as reported)15,845,970
Long-term Assets  (calculated)0
+/- 15,845,970

Liabilities & Shareholders' Equity

Total Current Liabilities18,673,021
Long-term Liabilities2,380,528
Total Stockholder Equity49,415,942
Total Current Liabilities
Total Current Liabilities  (as reported)18,673,021
Total Current Liabilities  (calculated)0
+/- 18,673,021
Long-term Liabilities
Long-term Liabilities  (as reported)2,380,528
Long-term Liabilities  (calculated)0
+/- 2,380,528
Total Stockholder Equity
Total Stockholder Equity (as reported)49,415,942
Total Stockholder Equity (calculated)0
+/- 49,415,942
Other
Common Stock Shares Outstanding 8,611
Net Invested Capital 49,415,942
Net Working Capital 35,950,500



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
46,503,880
53,303,510
48,307,769
48,350,789
48,107,187
48,016,868
47,322,839
47,342,870
46,871,276
47,382,195
51,770,849
49,210,506
50,413,140
50,635,947
50,142,911
59,157,362
56,369,279
58,936,238
60,844,748
59,542,775
70,839,343
77,186,757
74,795,461
72,627,064
71,670,379
72,109,584
70,136,977
67,932,582
72,013,503
72,930,017
72,614,903
62,085,249
59,740,494
58,099,861
56,392,661
60,367,781
61,944,902
61,642,348
63,841,457
64,040,932
64,164,140
65,954,308
67,422,026
66,016,893
69,369,043
70,469,490
70,469,49069,369,04366,016,89367,422,02665,954,30864,164,14064,040,93263,841,45761,642,34861,944,90260,367,78156,392,66158,099,86159,740,49462,085,24972,614,90372,930,01772,013,50367,932,58270,136,97772,109,58471,670,37972,627,06474,795,46177,186,75770,839,34359,542,77560,844,74858,936,23856,369,27959,157,36250,142,91150,635,94750,413,14049,210,50651,770,84947,382,19546,871,27647,342,87047,322,83948,016,86848,107,18748,350,78948,307,76953,303,51046,503,880
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,185,448
28,639,632
30,971,411
42,533,243
49,427,716
48,291,787
48,130,967
47,720,995
47,966,936
46,345,468
43,862,124
47,152,501
47,473,504
46,543,892
45,470,440
40,711,441
40,070,707
38,693,189
42,175,437
44,134,343
43,452,255
46,208,025
46,269,473
46,105,690
48,530,553
50,281,936
49,281,216
52,713,374
54,623,521
54,623,52152,713,37449,281,21650,281,93648,530,55346,105,69046,269,47346,208,02543,452,25544,134,34342,175,43738,693,18940,070,70740,711,44145,470,44046,543,89247,473,50447,152,50143,862,12446,345,46847,966,93647,720,99548,130,96748,291,78749,427,71642,533,24330,971,41128,639,63227,185,44800000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,704,150
6,729,527
5,471,937
5,786,865
12,204,193
12,408,696
10,034,766
9,397,635
8,746,817
6,686,697
5,623,641
7,479,387
5,271,317
7,363,987
8,793,908
7,149,335
7,296,874
7,299,093
7,430,210
0
0
0
7,430,132
7,111,771
10,518,089
9,964,600
8,750,763
8,960,551
0
08,960,5518,750,7639,964,60010,518,0897,111,7717,430,1320007,430,2107,299,0937,296,8747,149,3358,793,9087,363,9875,271,3177,479,3875,623,6416,686,6978,746,8179,397,63510,034,76612,408,69612,204,1935,786,8655,471,9376,729,5276,704,15000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,520,000
5,195,000
8,970,000
16,355,000
16,660,000
17,365,000
20,570,000
20,985,000
19,745,000
20,605,000
19,415,000
0
0
17,591,000
15,343,000
13,335,000
5,750,000
6,875,000
6,860,000
7,265,000
4,590,000
3,795,000
5,360,000
6,730,000
6,335,000
11,005,000
13,265,000
14,342,000
0
014,342,00013,265,00011,005,0006,335,0006,730,0005,360,0003,795,0004,590,0007,265,0006,860,0006,875,0005,750,00013,335,00015,343,00017,591,0000019,415,00020,605,00019,745,00020,985,00020,570,00017,365,00016,660,00016,355,0008,970,0005,195,0004,520,00000000000000000000
       Net Receivables 
8,747,484
9,047,497
9,158,051
9,006,538
8,091,509
9,107,553
7,653,539
8,512,334
7,494,053
8,692,543
10,124,738
8,981,889
8,749,995
8,491,631
8,532,349
8,532,921
8,218,918
8,984,807
9,224,007
8,745,465
11,820,147
11,930,901
9,876,975
9,028,953
9,020,405
11,078,761
8,624,624
7,912,076
9,283,272
10,109,311
9,921,901
6,899,239
8,100,738
10,351,227
9,621,984
10,370,589
13,412,139
11,992,812
13,514,867
14,151,379
12,257,803
13,117,200
0
11,587,691
11,889,301
0
011,889,30111,587,691013,117,20012,257,80314,151,37913,514,86711,992,81213,412,13910,370,5899,621,98410,351,2278,100,7386,899,2399,921,90110,109,3119,283,2727,912,0768,624,62411,078,7619,020,4059,028,9539,876,97511,930,90111,820,1478,745,4659,224,0078,984,8078,218,9188,532,9218,532,3498,491,6318,749,9958,981,88910,124,7388,692,5437,494,0538,512,3347,653,5399,107,5538,091,5099,006,5389,158,0519,047,4978,747,484
       Other Current Assets 
394,620
138,683
210,500
375,484
338,355
201,877
605,658
516,816
587,502
734,001
425,272
710,113
315,883
323,729
161,733
137,307
469,633
210,605
256,823
196,430
191,660
172,113
226,487
109,468
94,054
43,474
277,211
54,237
94,128
287,228
427,006
698,855
1,137,148
335,868
430,970
298,045
209,328
1,355,625
928,134
3,300,000
3,300,000
3,418,678
314,589
0
0
0
000314,5893,418,6783,300,0003,300,000928,1341,355,625209,328298,045430,970335,8681,137,148698,855427,006287,22894,12854,237277,21143,47494,054109,468226,487172,113191,660196,430256,823210,605469,633137,307161,733323,729315,883710,113425,272734,001587,502516,816605,658201,877338,355375,484210,500138,683394,620
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,771,459
18,058,450
17,423,755
17,140,090
16,735,676
16,655,669
15,845,970
15,845,97016,655,66916,735,67617,140,09017,423,75518,058,45017,771,459000000000000000000000000000000000000000
       Property Plant Equipment 
21,887,439
21,901,709
20,917,956
20,334,235
20,158,679
19,397,712
19,606,929
19,824,028
19,625,886
19,648,719
20,274,758
20,026,119
20,115,596
20,018,126
19,153,258
20,100,699
19,025,414
19,198,867
19,117,709
18,346,512
18,097,050
18,446,507
18,100,063
17,930,265
17,773,368
18,200,333
18,558,728
18,768,650
20,287,914
20,700,765
21,144,038
12,909,891
14,721,229
14,859,181
14,709,168
14,899,900
14,786,152
14,750,839
14,467,490
14,614,749
14,623,174
14,469,649
14,313,018
14,159,475
14,138,322
0
014,138,32214,159,47514,313,01814,469,64914,623,17414,614,74914,467,49014,750,83914,786,15214,899,90014,709,16814,859,18114,721,22912,909,89121,144,03820,700,76520,287,91418,768,65018,558,72818,200,33317,773,36817,930,26518,100,06318,446,50718,097,05018,346,51219,117,70919,198,86719,025,41420,100,69919,153,25820,018,12620,115,59620,026,11920,274,75819,648,71919,625,88619,824,02819,606,92919,397,71220,158,67920,334,23520,917,95621,901,70921,887,439
       Goodwill 
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
589,544
0
0
0
000589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544589,544
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,718,620
11,242,612
8,313,692
8,391,502
7,376,943
6,424,889
4,640,698
4,094,466
3,868,438
3,149,539
3,107,353
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000003,107,3533,149,5393,868,4384,094,4664,640,6986,424,8897,376,9438,391,5028,313,69211,242,61210,718,62000000000000000000
       Intangible Assets 
932,728
933,308
932,383
931,151
930,644
931,447
930,508
933,910
932,830
933,570
887,982
886,905
885,828
884,751
883,674
887,645
922,189
915,173
914,078
891,105
863,539
272,929
271,863
270,797
269,730
268,731
267,765
304,325
199,338
196,579
202,133
198,943
196,115
199,257
199,108
199,066
200,375
413,461
399,213
398,294
679,479
663,632
647,826
632,019
616,224
0
0616,224632,019647,826663,632679,479398,294399,213413,461200,375199,066199,108199,257196,115198,943202,133196,579199,338304,325267,765268,731269,730270,797271,863272,929863,539891,105914,078915,173922,189887,645883,674884,751885,828886,905887,982933,570932,830933,910930,508931,447930,644931,151932,383933,308932,728
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
-1
0
0
00-1000-1000000000000000000000000000000000000000
> Total Liabilities 
25,347,444
30,010,259
25,375,508
25,251,871
25,912,490
25,128,564
24,419,903
23,922,583
23,207,606
22,061,357
25,227,331
22,584,370
22,619,284
22,194,159
20,765,371
22,621,851
20,972,081
21,646,733
22,109,812
21,487,220
27,827,262
30,598,844
28,283,732
27,320,572
27,283,576
27,657,824
23,547,520
21,003,505
25,914,733
26,105,214
25,180,924
17,042,252
15,525,608
13,934,689
12,363,020
16,422,575
17,822,513
17,284,723
19,925,160
18,314,887
17,726,914
18,911,958
19,602,412
17,712,145
20,256,912
21,053,549
21,053,54920,256,91217,712,14519,602,41218,911,95817,726,91418,314,88719,925,16017,284,72317,822,51316,422,57512,363,02013,934,68915,525,60817,042,25225,180,92426,105,21425,914,73321,003,50523,547,52027,657,82427,283,57627,320,57228,283,73230,598,84427,827,26221,487,22022,109,81221,646,73320,972,08122,621,85120,765,37122,194,15922,619,28422,584,37025,227,33122,061,35723,207,60623,922,58324,419,90325,128,56425,912,49025,251,87125,375,50830,010,25925,347,444
   > Total Current Liabilities 
10,578,314
13,721,274
10,798,536
9,321,260
9,584,825
9,435,780
8,323,149
13,012,424
12,128,967
10,824,994
13,342,799
10,853,929
11,352,007
12,976,846
12,097,262
11,534,630
10,568,421
11,340,402
11,709,576
12,245,519
15,009,706
16,792,089
14,390,014
14,030,387
13,628,463
13,781,345
12,609,722
9,941,811
13,879,969
14,811,508
13,811,748
7,679,606
8,819,675
12,492,130
10,930,672
14,138,519
15,535,974
14,134,771
16,240,636
15,920,095
15,183,844
15,069,116
15,721,083
14,513,177
17,051,365
18,673,021
18,673,02117,051,36514,513,17715,721,08315,069,11615,183,84415,920,09516,240,63614,134,77115,535,97414,138,51910,930,67212,492,1308,819,6757,679,60613,811,74814,811,50813,879,9699,941,81112,609,72213,781,34513,628,46314,030,38714,390,01416,792,08915,009,70612,245,51911,709,57611,340,40210,568,42111,534,63012,097,26212,976,84611,352,00710,853,92913,342,79910,824,99412,128,96713,012,4248,323,1499,435,7809,584,8259,321,26010,798,53613,721,27410,578,314
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,414,899
12,163,462
12,568,240
18,096,539
18,882,232
0
0
0
0
5,762,205
2,738,115
4,556,985
6,696,102
6,347,360
4,351,808
2,697,736
4,422,325
6,857,487
8,042,300
8,965,415
8,227,598
10,292,690
9,485,938
9,023,452
8,187,477
0
0
0
0
00008,187,4779,023,4529,485,93810,292,6908,227,5988,965,4158,042,3006,857,4874,422,3252,697,7364,351,8086,347,3606,696,1024,556,9852,738,1155,762,205000018,882,23218,096,53912,568,24012,163,46211,414,89900000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,414,899
12,163,462
12,568,240
18,096,539
18,882,232
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,645,008
10,182,522
10,221,547
10,409,454
9,238,516
10,554,724
0
010,554,7249,238,51610,409,45410,221,54710,182,52210,645,0080000000000000000018,882,23218,096,53912,568,24012,163,46211,414,89900000000000000000
       Accounts payable 
2,423,459
3,426,242
1,798,350
2,488,487
2,047,031
2,070,500
2,395,627
3,152,016
2,903,685
2,946,924
4,009,796
3,707,865
4,573,963
4,580,967
3,933,758
4,235,156
3,770,743
4,283,044
4,022,630
3,693,422
3,622,461
3,805,365
3,709,850
3,547,390
2,702,679
3,063,041
2,769,791
2,709,303
3,763,307
3,880,921
2,828,556
1,670,797
2,602,037
3,944,166
2,618,918
4,751,589
5,034,413
4,314,274
4,326,905
3,901,171
3,618,028
0
0
3,539,648
4,556,910
0
04,556,9103,539,648003,618,0283,901,1714,326,9054,314,2745,034,4134,751,5892,618,9183,944,1662,602,0371,670,7972,828,5563,880,9213,763,3072,709,3032,769,7913,063,0412,702,6793,547,3903,709,8503,805,3653,622,4613,693,4224,022,6304,283,0443,770,7434,235,1563,933,7584,580,9674,573,9633,707,8654,009,7962,946,9242,903,6853,152,0162,395,6272,070,5002,047,0312,488,4871,798,3503,426,2422,423,459
       Other Current Liabilities 
1,752,371
2,913,490
3,116,999
1,401,409
1,274,857
1,502,333
1,704,528
3,250,942
3,763,598
3,665,933
4,098,743
3,574,994
3,086,657
4,062,421
3,963,584
3,987,095
3,801,942
3,887,648
3,820,042
3,735,608
5,261,220
6,092,672
6,067,676
5,987,711
5,294,946
3,796,416
3,323,518
3,575,599
4,746,161
3,530,222
3,923,134
1,055,818
2,847,985
3,390,392
742,283
716,498
704,179
818,150
790,560
-1
0
334,910
106,768
0
0
0
000106,768334,9100-1790,560818,150704,179716,498742,2833,390,3922,847,9851,055,8183,923,1343,530,2224,746,1613,575,5993,323,5183,796,4165,294,9465,987,7116,067,6766,092,6725,261,2203,735,6083,820,0423,887,6483,801,9423,987,0953,963,5844,062,4213,086,6573,574,9944,098,7433,665,9333,763,5983,250,9421,704,5281,502,3331,274,8571,401,4093,116,9992,913,4901,752,371
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,394,792
2,543,070
3,842,842
3,881,329
3,198,968
3,205,547
2,380,528
2,380,5283,205,5473,198,9683,881,3293,842,8422,543,0702,394,792000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,623,584
14,505,998
15,616,798
15,163,235
15,153,559
1,182,148
3,699,188
1,206,807
1,175,154
2,147,056
2,147,056
3,010,509
3,505,078
2,341,772
2,489,530
3,786,900
0
0
0
0
00003,786,9002,489,5302,341,7723,505,0783,010,5092,147,0562,147,0561,175,1541,206,8073,699,1881,182,14815,153,55915,163,23515,616,79814,505,99813,623,58400000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-11,414,899
-12,163,462
-12,568,240
-18,096,539
-18,882,232
0
0
0
0
-5,762,205
-2,738,115
-4,556,985
-6,696,102
-6,347,360
-4,351,808
-2,697,736
-4,422,325
-6,857,487
-8,042,300
-8,965,415
-8,227,598
-10,292,690
-9,431,300
-8,743,390
-7,939,143
303,236
267,995
281,086
0
0281,086267,995303,236-7,939,143-8,743,390-9,431,300-10,292,690-8,227,598-8,965,415-8,042,300-6,857,487-4,422,325-2,697,736-4,351,808-6,347,360-6,696,102-4,556,985-2,738,115-5,762,2050000-18,882,232-18,096,539-12,568,240-12,163,462-11,414,89900000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000
> Total Stockholder Equity
19,562,972
22,767,073
22,609,898
23,089,820
22,533,120
23,309,248
23,623,592
24,396,660
24,898,739
27,007,878
28,500,904
28,836,234
30,331,728
30,955,766
31,546,974
39,022,061
37,777,514
39,675,829
41,039,155
40,488,548
45,593,348
49,283,448
49,150,875
47,963,496
47,175,539
47,439,415
46,589,458
46,929,077
46,098,770
46,824,803
47,433,979
45,042,997
44,214,886
44,165,172
44,029,642
43,945,206
44,122,389
44,357,625
43,916,297
45,726,044
46,437,227
47,042,350
47,819,614
48,304,748
49,112,131
49,415,942
49,415,94249,112,13148,304,74847,819,61447,042,35046,437,22745,726,04443,916,29744,357,62544,122,38943,945,20644,029,64244,165,17244,214,88645,042,99747,433,97946,824,80346,098,77046,929,07746,589,45847,439,41547,175,53947,963,49649,150,87549,283,44845,593,34840,488,54841,039,15539,675,82937,777,51439,022,06131,546,97430,955,76630,331,72828,836,23428,500,90427,007,87824,898,73924,396,66023,623,59223,309,24822,533,12023,089,82022,609,89822,767,07319,562,972
   Common Stock
3,065,000
3,397,594
3,397,594
3,397,594
3,397,594
3,397,594
3,397,594
3,508,459
3,619,323
3,951,917
4,173,646
4,173,645
4,305,294
4,305,294
4,305,294
4,305,293
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
4,305,294
0
0
0
0
00004,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2944,305,2934,305,2944,305,2944,305,2944,173,6454,173,6463,951,9173,619,3233,508,4593,397,5943,397,5943,397,5943,397,5943,397,5943,397,5943,065,000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,799,591
14,799,591
14,799,591
14,799,591
14,799,591
14,834,724
14,834,724
14,813,932
14,813,932
14,488,509
14,488,509
14,488,509
14,488,509
14,576,006
14,576,006
14,576,006
0
0
0
0
000014,576,00614,576,00614,576,00614,488,50914,488,50914,488,50914,488,50914,813,93214,813,93214,834,72414,834,72414,799,59114,799,59114,799,59114,799,59114,799,59100000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000-492,934
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,388,784
5,867,158
5,981,305
5,079,630
11,993,593
11,079,063
10,160,394
9,686,483
9,373,982
-222,391
8,520,809
8,147,170
8,438,556
8,510,399
9,059,270
8,948,270
9,031,190
8,950,190
8,960,990
8,774,726
8,806,550
8,728,862
0
0
8,746,495
0
0
0
0
00008,746,495008,728,8628,806,5508,774,7268,960,9908,950,1909,031,1908,948,2709,059,2708,510,3998,438,5568,147,1708,520,809-222,3919,373,9829,686,48310,160,39411,079,06311,993,5935,079,6305,981,3055,867,1585,388,78400000000000000000



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue79,476,916
Cost of Revenue-65,683,964
Gross Profit13,792,95213,792,952
 
Operating Income (+$)
Gross Profit13,792,952
Operating Expense-75,461,046
Operating Income4,015,870-61,668,093
 
Operating Expense (+$)
Research Development837,216
Selling General Administrative5,574,919
Selling And Marketing Expenses0
Operating Expense75,461,0466,412,135
 
Net Interest Income (+$)
Interest Income669,559
Interest Expense-581,379
Other Finance Cost-0
Net Interest Income88,180
 
Pretax Income (+$)
Operating Income4,015,870
Net Interest Income88,180
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,374,0924,015,870
EBIT - interestExpense = -581,379
2,591,396
3,172,775
Interest Expense581,379
Earnings Before Interest and Taxes (EBIT)03,955,471
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax3,374,092
Tax Provision-782,696
Net Income From Continuing Ops2,591,3962,591,396
Net Income2,591,396
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-88,180
 

Technical Analysis of Genebiotech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genebiotech. The general trend of Genebiotech is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genebiotech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GeneBioTech Co. Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3,500 < 3,695 < 3,700.

The bearish price targets are: 3,270 > 3,125.

Tweet this
GeneBioTech Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GeneBioTech Co. Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GeneBioTech Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GeneBioTech Co. Ltd. The current macd is -13.82480362.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genebiotech price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genebiotech. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genebiotech price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
GeneBioTech Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGeneBioTech Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GeneBioTech Co. Ltd. The current adx is 38.74.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Genebiotech shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
GeneBioTech Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GeneBioTech Co. Ltd. The current sar is 3,650.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GeneBioTech Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GeneBioTech Co. Ltd. The current rsi is 50.32. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
GeneBioTech Co. Ltd Daily Relative Strength Index (RSI) ChartGeneBioTech Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GeneBioTech Co. Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genebiotech price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
GeneBioTech Co. Ltd Daily Stochastic Oscillator ChartGeneBioTech Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GeneBioTech Co. Ltd. The current cci is -27.89578023.

GeneBioTech Co. Ltd Daily Commodity Channel Index (CCI) ChartGeneBioTech Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GeneBioTech Co. Ltd. The current cmo is 5.74173659.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
GeneBioTech Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartGeneBioTech Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GeneBioTech Co. Ltd. The current willr is -51.28205128.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genebiotech is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GeneBioTech Co. Ltd Daily Williams %R ChartGeneBioTech Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GeneBioTech Co. Ltd.

GeneBioTech Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GeneBioTech Co. Ltd. The current atr is 121.55.

GeneBioTech Co. Ltd Daily Average True Range (ATR) ChartGeneBioTech Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GeneBioTech Co. Ltd. The current obv is 46,876,600.

GeneBioTech Co. Ltd Daily On-Balance Volume (OBV) ChartGeneBioTech Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GeneBioTech Co. Ltd. The current mfi is 33.93.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
GeneBioTech Co. Ltd Daily Money Flow Index (MFI) ChartGeneBioTech Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GeneBioTech Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-20ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-09-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-07MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

GeneBioTech Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GeneBioTech Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.320
Ma 20Greater thanMa 503,452.750
Ma 50Greater thanMa 1003,469.700
Ma 100Greater thanMa 2003,651.200
OpenGreater thanClose3,435.000
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Genebiotech with someone you think should read this too:
  • Are you bullish or bearish on Genebiotech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genebiotech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GeneBioTech Co. Ltd

I send you an email if I find something interesting about GeneBioTech Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about GeneBioTech Co. Ltd.

Receive notifications about GeneBioTech Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.